Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: Structure transport relationships

European Journal of Pharmaceutical Sciences

Volumn 20, Issue 3, 2003, Pages 347-356

  Schaddelee, Marloes P ^a   Voorwinden, Heleen L ^a   Groenendaal, Dorien ^a   Hersey, Anne ^b   Ijzerman, Adriaan P ^a   Danhof, Meindert ^a   De Boer, Albertus G ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

A1 receptor; Blood brain barrier transport; Equilibrative nucleoside transporter; Physicochemical properties

Indexed keywords

BLOOD; BRAIN; CELLS; CHEMICAL MODIFICATION; DIFFUSION;

ABRAHAM EQUATIONS;

DRUG DOSAGE;

(4 NITROBENZYL) 6 THIOINOSINE; 2' DEOXY N 6 CYCLOPENTYLADENOSINE; 3' DEOXY N 6 CYCLOPENTYLADENOSINE; 6 N CYCLOPENTYLADENOSINE; 8 (BUTYLAMINO) N 6 CYCLOPENTYLADENOSINE; 8 (ETHYLAMINO) N 6 CYCLOPENTYLADENOSINE; 8 (METHYLAMINO) N 6 CYCLOPENTYLADENOSINE; 8 (PROPYLAMINO) N 6 CYCLOPENTYLADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; CYCLOHEXYLADENOSINE; INOSINE DERIVATIVE; N 6 CYCLOBUTYLADENOSINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CHEMICAL MODIFICATION; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DIFFUSION; DRUG TRANSPORT; ENDOTHELIUM CELL; MATHEMATICAL ANALYSIS; NEWBORN; NONHUMAN; NONLINEAR SYSTEM; PREDICTION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; REGRESSION ANALYSIS; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 0242302565     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2003.08.003     Document Type: Article

References (41)

1. Abraham M.H., Weathersby P.K. Hydrogen bonding. 30. Solubility of gases and vapors in biological liquids and tissues. J. Pharm. Sci. 83:1994;1450-1456.
2. Abraham M.H., Chadha H.S., Mitchell R.C. Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J. Pharm. Sci. 83:1994;1257-1268.
3. Barros L.F., Yudilevich D.L., Yarvis S.M., Beaumont N., Young J.D., Balswin S.A. Immunolocalization of nucleoside transporters in human placental trophoblast and endothelial cells: evidence for multiple transporter isoforms. Pfugers Arch. Eur. J. Pysiol. 429:1995;394-399.
4. Cass C.E., Young J.D., Baldwin S.A. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem. Cell Biol. 76:1998;761-770.
5. Clark D.E. Rapid calculation of polar molecular surface area its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88:1999;815-821.
6. Crawford C.R., Patel D.H., Naeve C., Belt J.A. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J. Biol. Chem. 273:1998;5288-5293.
7. Gaillard P.J., De Boer A.G., Breimer D.D. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur. J. Pharm. Sci. 12:2000;95-102.
8. Gaillard P.J., Van der Sandt I.C., Voorwinden L.H., Vu D., Nielsen J.L., De Boer A.G., Breimer D.D. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res. 17:2000a;1198-1205.
9. Gaillard P.J., Voorwinden L.H., Nielsen J., Ivanov A., Atsumi R., Engman H., Ringbom C., De Boer A.G., Breimer D.D. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. J. Pharm. Sci. 12:2000b;215-222.
10. Gu G., Nath A., Geiger J.D. Characterization of inhibitor-sensitive and -resistent adenosine tranporters in cultured human fetal astrocytes. J. Neurochem. 3:1996;972-977.
11. Janzer R.C., Raff M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 325:1987;253-257.
12. Jennings L.L., Hao C., Cabrita M.A., Vickers M.F., Baldwin S.A., Young J.D., Cass C.E. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology. 40:2001;722-731.
13. Kalaria R.N., Harik S.I. Adenosine receptors and the nucleoside transporter. J. Cereb. Blood Flow Metab. 8:1988;32-39.
14. Kaliszan R., Markuszewki M. Brain/blood distribution described by a combination of partition coefficient and molecular mass. Int. J. Pharm. 145:1996;9-16.
15. Kelder J., Grootenhuis P.D., Bayada D.M., Delbressine L.P., Ploemen J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16:1999;1514-1519.
16. Lee G., Dallas S., Hong M., Bendayan R. Drug Transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:2001;569-596.
17. + nucleoside cotransporter CNT2. J. Cereb. Blood Flow Metab. 21:2001;929-936.
18. Madara J.L. Regulation of the movement of solutes across tight junctions. Annu. Rev. Physiol. 60:1998;143-159.
19. Malhotra J., Gupta Y.K. Effect of adenosine receptor modulation on pentylenetetrazole-induced seizure rats. Br. J. Pharmacol. 120:1997;282-288.
20. 1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. J. Chromatogr. 620:1993;113-120.
21. Moser G.H., Schrader J., Deussen A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol. 256:1989;C799-806.
22. Palm K., Luthman K., Ungell A.L., Strandlund G., Beigi F., Lundahl P., Artursson P. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. Med. Chem. 41:1998;5382-5392.
23. Pardrigde, W.M., 1991. Peptide Drug Delivery into the Brain. Raven Press, New York.
24. Pavan B., IJzerman A.P. Processing of adenosine receptor agonists in rat and human whole blood. Biochem. Pharm. 56:1998;1625-1632.
25. 1 receptor. J. Med. Chem. 39:1996;1463-1471.
26. Sawynok J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 317:1998;1-11.
27. Schaddelee M.P., Voorwinden H.L., Van Tilburg E.W., Pateman T.J., IJzerman A.P., Danhof M., De Boer A.G. The functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives. Eur. J. Pharm. Sci. 19:2003;13-22.
28. Sjölund K.F., Belfrage M., Karlsten R., Segerdahl M., Arner S., Gordh T., Solevi A. Systemic adenosine infusion reduces the area of tactile allodynia in neuropathic pain following peripheral nerve injury: a multi-centre, placebo-controlled study. Eur. J. Pain. 5:2001;199-207.
29. Strecker R.E., Morairty S., Thakkar M.M., Porkka-Heiskanen T., Basheer R., Dauphin L.J., Rainnie D.G., Portas C.M., Greene R.W., McCarley R.W. Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav. Brain Res. 115:2000;183-204.
30. Tamai I., Tsuji A. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 36:1999;277-290.
31. Tamai I., Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89:2000;1371-1388.
32. Thorn J.A., Jarvis S.M. Adenosine transporters. Gen. Pharmacol. 27:1996;613-620.
33. Van Bree J.B.M.M., De Boer A.G., Danhof M., Ginsel L.A., Breimer D.D. Characterization of an in vitro blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J. Pharmacol. Exp. Ther. 241:1988;1233-1239.
34. 1 receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J. Pharm. Exp. Ther. 290:1999;702-709.
35. Van der Sandt I.C.J., Vos C.M.P., Nabulsi L., Blom-Roosemalen M.C.M., Voorwinden L.H., De Boer A.G., Breimer D.D. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS. 15:2001;483-491.
36. Van der Wenden E.M., Hartog-Witte H.R., Roelen H.C.P.F., Von Frijtag Drabbe Künzel J.K., Mathôt R.A.A., IJzerman A.P. Ribose-modified adenosine analogues as potential partial agonists for adenosine receptor. J. Med. Chem. 38:1995;4000-4006.
37. Von Lubitz D.K. Adenosine in the treatment of stroke: yes, maybe, or absolutely not. Expert Opin. Investig. Drugs. 10:2001;619-632.
38. Von Lubitz D.K., Lin R.C., Bischofberger N., Beenhakker M., Boyd M., Lipartowska R., Jacobson K.A. Protection against ischemic damage by adenosine amine congener a potent and selective adenosine A1 receptor agonist. Eur. J. Pharmacol. 369:1999;313-317.
39. Ward J.L., Sheraldi A., Mo Z.-P., Tse C.-M. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. J. Biol. Chem. 275:2000;8375-8381.
40. Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 6:1998;151-165.
41. Young R.C., Mitchell R.C., Brown T.H., Ganellin C.R., Griffiths R., Jones M., Rana K.K., Saunders D., Smith I.R., Sore N.E. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J. Med. Chem. 31:1988;656-671.